Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
DPT vaccine
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== DTaP === DTaP (also DTP and TDaP) is a combination vaccine against diphtheria, tetanus, and pertussis, in which the pertussis component is acellular.<ref name="cdc.gov">{{cite web |title=Safety Information for Diphtheria, Tetanus, and Pertussis Vaccines |url=https://www.cdc.gov/vaccinesafety/vaccines/dtap-tdap-vaccine.html |date=15 June 2020 |access-date=28 July 2020 |website=U.S. [[Centers for Disease Control and Prevention]] (CDC) |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805023732/https://www.cdc.gov/vaccinesafety/vaccines/dtap-tdap-vaccine.html |url-status=live }} {{PD-notice}}</ref> This is in contrast to whole-cell, inactivated DTP (or DTwP).<ref name=iran-choice>{{cite journal | vauthors = Syed MA | title = Choosing from Whole Cell and Acellular Pertussis Vaccines-Dilemma for the Developing Countries | journal = Iranian Journal of Public Health | volume = 46 | issue = 2 | pages = 272β273 | date = February 2017 | pmid = 28451568 | pmc = 5402791 }}</ref> The acellular vaccine uses selected antigens of the pertussis pathogen to induce immunity.<ref name="Esposito">{{cite journal | vauthors = Esposito S, Stefanelli P, Fry NK, Fedele G, He Q, Paterson P, Tan T, Knuf M, Rodrigo C, Weil Olivier C, Flanagan KL, Hung I, Lutsar I, Edwards K, O'Ryan M, Principi N | title = Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines | journal = Frontiers in Immunology | volume = 10 | pages = 1344 |year = 2019 | pmid = 31333640 | pmc = 6616129 | doi = 10.3389/fimmu.2019.01344 | doi-access = free }}</ref> Because it uses fewer antigens than the [[whole-cell vaccine]]s, it is considered to cause fewer side effects, but it is also more expensive.<ref name="Esposito"/> Research suggests that the DTwP vaccine is more effective than DTaP in conferring immunity, because DTaP's narrower antigen base is less effective against current pathogen strains.<ref name=narrower>{{cite web|year=2020|title=Diphtheria, Tetanus, and Whooping Cough Vaccination|url=https://www.cdc.gov/vaccines/vpd/dtap-tdap-td/public/index.html|access-date=4 August 2020|publisher=U.S. [[Centers for Disease Control and Prevention]] (CDC)|archive-date=11 August 2020|archive-url=https://web.archive.org/web/20200811164121/https://www.cdc.gov/vaccines/vpd/dtap-tdap-td/public/index.html|url-status=live}}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)